<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05035706</url>
  </required_header>
  <id_info>
    <org_study_id>2021-0037</org_study_id>
    <secondary_id>NCI-2021-08685</secondary_id>
    <secondary_id>2021-0037</secondary_id>
    <nct_id>NCT05035706</nct_id>
  </id_info>
  <brief_title>Anti-Leukemia Immune Responses After Irradiation of Extramedullary Tumors</brief_title>
  <official_title>Anti-Leukemia Immune Responses After Irradiation of Extramedullary Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial assesses how the immune system responds to leukemia tumors after low dose&#xD;
      radiation delivered as part of standard of care. The information learned in this study may&#xD;
      help them know if adding immunotherapy (a type of treatment that uses the immune system to&#xD;
      fight cancer) can be helpful in future leukemia patients receiving radiation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To identify changes in anti-leukemia immune responses after local radiotherapy to&#xD;
      extramedullary sites.&#xD;
&#xD;
      II. Develop an annotated biospecimen panel of extramedullary leukemia biopsies prior to and&#xD;
      after radiotherapy to examine local immune responses using transcriptional profiling,&#xD;
      immunofluorescence and single cell analyses.&#xD;
&#xD;
      III. Define changes in the T cell receptor (TCR) clonotypes, functionality and inflammatory&#xD;
      cytokine levels in peripheral blood leukocytes and serum.&#xD;
&#xD;
      IV. Correlate changes in anti-tumor immune responses with clinic-pathological variables and&#xD;
      patient outcomes.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To assess the overall response rate (ORR= complete response [CR] + partial response [PR])&#xD;
      of the extramedullary tumor treated with radiation therapy.&#xD;
&#xD;
      II. To assess the CR of extramedullary tumor treated with radiation therapy. III. Determine&#xD;
      the duration of response (DOR), event-free survival (EFS).&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients undergo biopsy prior to radiation therapy and 7-14 days after radiation therapy.&#xD;
      Patients also undergo blood sample collection prior to therapy (within 7 days of starting&#xD;
      radiation therapy), 1 and 7 days post completion of radiation therapy. Patients' photographs&#xD;
      of the biopsy site are taken before and at 4-6 weeks post completion of radiation, and their&#xD;
      medical records are reviewed for up to 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 30, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2024</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in anti-leukemia immune responses</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Myeloid Leukemia</condition>
  <condition>Recurrent Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Treatment (biopsy, biospecimen collection)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo biopsy prior to radiation therapy and 7-14 days after radiation therapy. Patients also undergo blood sample collection prior to therapy (within 7 days of starting radiation therapy), 1 and 7 days post completion of radiation therapy. Patients' photographs of the biopsy site are taken before and at 4-6 weeks post completion of radiation, and their medical records are reviewed for up to 2 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biopsy</intervention_name>
    <description>Undergo biopsy</description>
    <arm_group_label>Treatment (biopsy, biospecimen collection)</arm_group_label>
    <other_name>BIOPSY_TYPE</other_name>
    <other_name>Bx</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biospecimen Collection</intervention_name>
    <description>Undergo blood and tissue sample collection</description>
    <arm_group_label>Treatment (biopsy, biospecimen collection)</arm_group_label>
    <other_name>Biological Sample Collection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Electronic Health Record Review</intervention_name>
    <description>Medical records reviewed</description>
    <arm_group_label>Treatment (biopsy, biospecimen collection)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Photography</intervention_name>
    <description>Photographs taken</description>
    <arm_group_label>Treatment (biopsy, biospecimen collection)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients diagnosed with new or recurrent myeloid leukemia&#xD;
&#xD;
          -  Aged &gt;= 18 years old&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status &lt; 4&#xD;
&#xD;
          -  Patient have measurable and amenable to biopsy under local anesthesia without the need&#xD;
             for imaging directed procedure&#xD;
&#xD;
          -  Ability to understand and provide signed informed consent&#xD;
&#xD;
          -  Females must be surgically or biologically sterile or postmenopausal (amenorrhoeic for&#xD;
             at least 12 months) or if of childbearing potential, must have a negative serum or&#xD;
             urine pregnancy test within 72 hours before the start of the treatment. Women of&#xD;
             childbearing potential must agree to use an adequate method of contraception during&#xD;
             the study and until the last radiation treatment. Males must be surgically or&#xD;
             biologically sterile or agree to use an adequate method of contraception during the&#xD;
             study and until the last radiation treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are unwilling to participate&#xD;
&#xD;
          -  Patients unwilling to undergo the biopsy before or after radiotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bouthaina S Dabaja</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bouthaina S Dabaja</last_name>
    <phone>713-563-2406</phone>
    <email>bdabaja@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bouthaina S. Dabaja</last_name>
      <phone>713-563-2406</phone>
      <email>bdabaja@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Bouthaina S. Dabaja</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>M D Anderson Cancer Center</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 25, 2021</study_first_submitted>
  <study_first_submitted_qc>August 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2021</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

